Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

cannabis

  • Home
  •  
  • cannabis



  • Most Read
  • Latest Comments
  • Cronos all set to launch new version of app to sell cannabis
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Cronos all set to launch new version of app to sell cannabis
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Cronos all set to launch new version of app to sell cannabis
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Cronos all set to launch new version of app to sell cannabis
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Cronos all set to launch new version of app to sell cannabis
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    • News

  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • News

  • Melodiol moves to clear debt with $12m asset fire sale
    Melodiol moves to clear debt with $12m asset fire sale
    • News

  • Althea to make a splash in the US with new cannabis-based sodas
    Althea to make a splash in the US with new cannabis-based sodas
    • News

  • Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    • News

  • Cronos all set to launch new version of app to sell cannabis
    • News

    Cronos all set to launch new version of app to sell cannabis

    Cannabis consumers rejoice, medicinal cannabis provider Cronos Australia (ASX:CAU) is very close to finally releasing its Canview platform to make the procurement of the drug an easy affair. The roll-out is happening across stages with the first one comprising a number of order fulfilment upgrades, process improvements and other efficiencies. It was deployed internally within

    Read More
    Public
  • Althea launches highest-concentration cannabis medication
    • News

    Althea launches highest-concentration cannabis medication

    Growing in areas that matter, cannabis medication producer Althea Group (ASX: AGH) has been increasing its global distribution offerings with the launch of its latest products; the Althea CBD25 soft gel capsules and the THC25 dried flower. Product development is the cornerstone of market share leadership in an industry still in its infancy. With the

    Read More
    Public
  • Does IP ownership of MDMA compounds reduce its potential for healthcare benefits?
    • Opinion

    Does IP ownership of MDMA compounds reduce its potential for healthcare benefits?

    If you read my articles often, you would know that I can become quite laudatory when discussing small cap companies excelling in recreational drug regulation and using once illegal drugs to treat various mental health conditions and illnesses. Ranging from cannabis to psychedelics, and now, MDMA. Most of my articles surrounding this area follow the

    Read More
    Public
  • Althea Group delivering record year following expansion into global markets
    • News

    Althea Group delivering record year following expansion into global markets

    The cheers of the cannabis industry can be heard loud and clear as the demand for the plant continues to prop up their profits. The last few years have been huge for the industry as companies attempt to strengthen earnings by out-scaling competitors.  One company hoping to come out on top is Althea Group (ASX:

    Read More
    Public
  • ECS penetrates New Zealand market with latest shipment to Nubu
    • News

    ECS penetrates New Zealand market with latest shipment to Nubu

    The budding cannabis market in New Zealand continues to flourish as more Kiwis seek an alternative to standard pharmaceutical drugs. Now, just because trends are shifting doesn’t mean it is easier for patients to gain access to cannabis medication. To open up the world of cannabis therapy, New Zealand’s largest cannabis wholesaler is creating a

    Read More
    Public
  • Bod unveils its latest launch of cannabis treatment
    • News

    Bod unveils its latest launch of cannabis treatment

    Changes in regulation surrounding marijuana have sprouted a robust medical cannabis market showing no signs of slowing down globally.  Currently, the U.S. dominates the cannabis market where the majority of States started adopting the new trend for cannabis treatment in 2012. Australia has been late to the game; we only began easing laws in early

    Read More
    Public
  • «
  • ‹
  • 3
  • 4
  • 5
  • 6
  • 7
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.